We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-10 of 16

Capital Markets & Public Companies Quarterly: Expanding Relief under Smaller Reporting Company, Reg A and Rule 701, SEC Enforcement of Cybersecurity Disclosures and Other News
  • McDermott Will & Emery
  • USA
  • July 11 2018

During the previous quarter, the SEC acted to expand the number of companies that may rely on the “smaller reporting company” scaled disclosure regime

Fiduciary Rule Status in Doubt Following Conflicting Courts of Appeals Decisions
  • Kilpatrick Townsend & Stockton LLP
  • USA
  • March 16 2018

By: Todd Castleton and Sterling Perkinson The status of the Department of Labor’s (DOL) final regulation expanding the scope of fiduciary status due

Supreme Court Grants Certiorari (Again) to Address Circuit Split on FLSA Automobile Dealer Exemption
  • Jackson Lewis PC
  • USA
  • September 28 2017

After effectively “punting” on the issue last year, the U.S. Supreme Court has again granted certiorari to resolve a circuit split regarding whether

A Glimmer Of Hope: The Supreme Court Now Has A Chance To Resolve A Circuit Split And Pronounce That Mortgage Underwriters Qualify For The Administrative Exemption
  • Seyfarth Shaw LLP
  • USA
  • September 28 2017

As our readers may recall, we took issue with the Ninth Circuit’s July decision in McKeen-Chaplin v. Provident Bank, which held that mortgage

Petition for Supreme Court review filed in pharmaceutical sales rep case
  • Seyfarth Shaw LLP
  • USA
  • August 18 2011

On August 12, 2011, the plaintiffs in Christopher v. SmithKline Beecham Corp., filed a petition for writ of certiorari with the U.S. Supreme Court seeking review of the 9th Circuit's decision holding that pharmaceutical sales representatives for GlaxoSmithKline are exempt from overtime as outside sales employees under the Fair Labor Standards Act.

Federal Courts consider FLSA exempt status of pharmaceutical sales representatives
  • Faegre Baker Daniels LLP
  • USA
  • April 28 2011

On July 6, 2010, the United States Court of Appeals for the Second Circuit decided In re Novartis Wage & Hour Litigation, 611 F.3d 141 (2d. Cir. 2010), holding that Novartis pharmaceutical sales representatives are not exempt from the requirements of the FLSA.

U.S. Supreme Court limits applicability of two FOIA exemptions
  • Holland & Knight LLP
  • USA
  • April 6 2011

The Freedom of Information Act (FOIA) requires federal agencies to make records available to the public, subject to nine exemptions.

Discrimination train has left the station: U.S. Supreme Court remands Alabama railroad case
  • Eversheds Sutherland (US) LLP
  • USA
  • March 21 2011

The U.S. Supreme Court reversed a U.S. Court of Appeals in holding that a railroad may bring suit to challenge the validity of a discriminatory Alabama sales tax exemption.

U.S. Supreme Court declines to resolve circuit split regarding administrative and outside sales exemptions under the FLSA
  • Dorsey & Whitney LLP
  • USA
  • March 4 2011

On February 28, 2011, the U.S. Supreme Court announced its decision to deny certiorari in the closely watched cases of Novartis Pharmaceuticals Corp. v. Lopes, No. 10-460, and Kuzinski v. Schering Corp., No. 10-459.

Supreme Court declines to review status of pharmaceutical sales reps. under the administrative or outside sales exemptions
  • Seyfarth Shaw LLP
  • USA
  • February 28 2011

At 10 a.m. EST today, the U.S. Supreme Court announced its decision to deny certiorari in Novartis Pharmaceuticals Corp. v. Lopes et al.